Compare

BPC-157 (Oral) vs Retatrutide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
XRedditFacebook

BPC-157 (Oral)

26 community reports

Positive 97% · Neutral 3% · Negative 0%

Most reported benefits

Recovery
157

Most reported side effects

Digestive upset
4

Dose distribution

Median: 600–1000 mcg · Most common: 1000–2000 mcg

0–25
0
25–50
0
50–100
0
100–200
0
200–400
50
400–600
6
600–1000
49
1000–2000
52
2000+
0

How repeat users are trending

Among repeat reporters, 90% said they felt similar to their last entry, 10% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 215 days · Based on 20 repeat reporters

Retatrutide

125 community reports

Positive 99% · Neutral 1% · Negative 0%

Most reported benefits

Appetite
222

Most reported side effects

Nausea
3

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
5
25–50
0
50–100
0
100–200
3
200–400
6
400–600
10
600–1000
5
1000–2000
80
2000+
113

How repeat users are trending

Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.

Overall, repeat reporters leaned similar or mixed compared to their previous entry.

Median gap between entries: 51 days · Based on 45 repeat reporters